Akeso, Summit Therapeutics Ink Potential $5B Deal to License Bispecific Antibody

Innovative antibody developer Akeso Inc. has entered into a partnership with oncology solutions company Summit Therapeutics to license the former’s breakthrough bispecific antibody, ivonescimab. The new agreement ties in nicely with Summit’s longstanding mission of developing and commercializing milestone oncology pipeline offerings...